New York, NY—February 23, 2006
The most common kind of wrist fracture is often caused by a fall onto an outstretched hand. Dubbed a FOOSH by orthopedic surgeons, these fractures may result from slipping on ice, as well as skiing and snowboarding injuries. Accounting for 17 percent of all emergency room visits, they can put anyone who braves the elements in harm’s way.
An innovative approach to treat these wrist fractures using a new biological compound called Chrysalin®, developed by OrthoLogic Corp., is now being studied in a randomized placebo-controlled multi-center trial underway at Hospital for Special Surgery (HSS) in Manhattan.
“When injected into the fracture, Chrysalin, a novel synthetic peptide, is thought to speed the process of bony healing and reduce the time that patients are required to wear casts or bulky fixation devices,” said Dr. Scott W. Wolfe, Attending Orthopedic Surgeon and Chief of the Hand Service at HSS. This new approach for fracture repair may offer patients a procedure that would enhance the rate of bone healing and minimize the need for prolonged immobilization.
“Traditionally, the time for healing of a wrist fracture averages six to eight weeks, and a bulky cast or external fixation device can inhibit mobility of the patient,” said Dr. Wolfe. “In the ideal candidate, Chrysalin may shorten the need for casting and allow an earlier return to function. Studies to date with Chrysalin have shown it to be a safe and effective product that restores bone strength and hand function. It has the potential to dramatically change the way orthopedists treat fractures,” said Dr. Wolfe.
Although there are no specific risks or diseases that increase the chance of getting a fracture, studies have shown that they frequently occur during sports activities. The use of protective gear such as wrist guards during activities like inline skating and snowboarding can decrease the chance of breaking a bone around the wrist.
“The wrist is a complex, unique and important joint,” said Dr. Wolfe. “Many fractures may go undetected and remain ununited for weeks or months.”
Without the hallmarks of injury such as pain or swelling, a seemingly invisible injury can turn into a debilitating one. Because of the potential for hidden dangers, extra vigilance should be paid to every wrist injury. Diagnostic tools such as physical examination and imaging techniques like X-ray, bone scan and MRI will help hand specialists determine the extent of injury.
Chrysalin is made by OrthoLogic, of Tempe, Ariz., which is funding the clinical trial.
National Public Radio conducted an interview with a patient who participated in this trial.
About HSS | Hospital for Special Surgery
HSS is the world’s leading academic medical center focused on musculoskeletal health. At its core is Hospital for Special Surgery, nationally ranked No. 1 in orthopedics for 14 years in a row and No. 2 in rheumatology by U.S.News & World Report (2023-2024). Founded in 1863, the Hospital has one of the lowest infection rates in the country and was the first in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center four consecutive times. The global standard total knee replacement was developed at HSS in 1969. An affiliate of Weill Cornell Medical College, HSS has a main campus in New York City and facilities in New Jersey, Connecticut and in the Long Island and Westchester County regions of New York State. In addition, HSS opened a new facility in Florida in early 2020. In 2019, HSS provided care to 151,000 patients and performed more than 35,000 surgical procedures, and people from all 50 U.S. states and 89 countries travelled to receive care at HSS. In addition to patient care, HSS leads the field in research, innovation and education. The HSS Research Institute comprises 20 translational research laboratories, 33 scientists, 10 clinician-scientists, 55 clinical investigators and 245 scientific support staff that drive the HSS research enterprise in the musculoskeletal “ecosystem,” neurology, pain management and rheumatic diseases. The HSS Innovation Institute was formed in 2016 to realize the potential of new drugs, therapeutics and devices. The HSS Education Institute is the world’s leading provider of education on musculoskeletal health, with its online learning platform offering more than 300 courses to more than 30,000 medical professional members worldwide. Through HSS Global Ventures, the institution is collaborating with medical centers and other organizations to advance the quality and value of musculoskeletal care and to make world-class HSS care more widely accessible nationally and internationally.
212.606.1197
mediarelations@hss.edu